PPPharmacy

Active

Private limited companyfounded 20215 yrs activeDe Pintelaan 164, 9000 Gent, BelgiumKBO/BCE: BE 0765.736.905

The computed 12-month bankruptcy probability of PPPharmacy is 1.6% (moderate). The 2025 annual accounts show equity of €85k and a net result of €50k. Equity is growing by ~25.9% per year across the filed fiscal years. Its solvency ranks better than 87% of 17987 sector peers (fiscal year 2025). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.

Watch Print / PDF

Checked score

Score 2025

90 / 100

Excellent▼ -10 vs 2024

The score combines four axes. Every signal that weighs is under Signals.

Axes · tick = 2024

Profitability100=

Solvency100=

Growth32▼-20

Stability94

Bankruptcy probability, 12 months

1.6% Moderate

0%0.5%1.5%4%10%≥ 25%

Credit up to €8k at 30 days acceptable

Liquidity ample (current ratio 4.73 against 11.3 in 2024), and 20.6% of the assets are financed with debt.

How do we compute the score and the probability?

Credit advice for your own amount and term

Signals

Six signals. The signal on the left, the evidence on the right.

−lowers risk+raises risk○neutral

Limited track record

This company has not been active as long as an established one and statistically fails somewhat more often.

KBO · incorporation date

Age against the risk zone

Higher-failure-rate sector

In this sector companies fail more often than the Belgian average.

Gazette · bankruptcies per sector, NACE 47

Relative position

BE, all sectors

reference

Sector 47

higher

← fewer bankruptcies more bankruptcies →

Annual accounts: healthy financial profile

The latest annual accounts show a healthy profile in solvency, result and liquidity.

NBB · annual accounts 2025

Solvency, return and age of the figures

Solvency

79.4%

Return on assets

46.8%

Age of the figures

14 mo

Latest accounts filed on time

The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 24-01-2026, 7 days ahead of the deadline.

NBB · 4 filings

Deviation from the deadline

2025

7 d early

2024

7 d early

2023

2 d early

2022

on the day

← before the deadline after the deadline →

The next deadline is still running

The next financial year closes on 30-06-2026 and is due by 31-01-2027. Nothing is late today.

Companies Code · seven months

Position in the running window

30-06-2026 close13-09-2026 today31-01-2027 deadline

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

Financials · fiscal year 2025, micro schema

Equity

€85k▼ 62.2%

2024 · €224k

2022: €86k 2023: €147k 2024: €224k

2022 → 2025

Total assets

€107k▼ 57.2%

2024 · €249k

2022: €125k 2023: €175k 2024: €249k

2022 → 2025

Net result

€50k▼ 35.1%

2024 · €77k

2022: €81k 2023: €61k 2024: €77k

2022 → 2025

Working capital

€81k▼ 62.8%

2024 · €218k

2022: €77k 2023: €139k 2024: €218k

2022 → 2025

Multi-year overview

Every figure with its change against the year before

▲ rise ▼ fall

Line2022202320242025Trend

Equity€86k-€147k▲ 70.7%€224k▲ 52.2%€85k▼ 62.2%

Operating result€103k-€77k▼ 25.2%€97k▲ 25.8%€63k▼ 34.6%

Net result€81k-€61k▼ 25.0%€77k▲ 26.1%€50k▼ 35.1%

Turnover and EBIT margin not published: the micro schema does not require them.

Result per fiscal year

Operating resultNet result

The operating result falls in 2025; 2025 is 35% below 2024 and is the lowest year so far.

Balance-sheet composition

2025 in colour, 2024 as the grey bar beneath

Assets €107k

96.3%

Fixed assets €4k▼ 60.8%

Current assets €103k▼ 57.0%

Equity and liabilities €107k

79.4%

20.6%

Equity €85k▼ 62.2%

Debt €22k▼ 12.4%

The debt ratio rises from 10.1% to 20.6%: equity shrinks faster than debt is paid down.

Key figures and ratios

2025 value · change against 2024

EBITDA

€70k▼

2024 · €103k

Cash flow

€56k▼

2024 · €83k

Solvency

79.4%▼

2024 · 89.9%

Current ratio

4.73▼

2024 · 11.30

Quick ratio

4.73▼

2024 · 11.30

Debt / equity

0.26▲

2024 · 0.11

ROE

58.9%▲

2024 · 34.3%

ROA

46.8%▲

2024 · 30.9%

Interest coverage

287.09▼

2024 · 432.83

Debt

€22k▼

2024 · €25k

Debt ≤ 1 year

€22k▲

2024 · €21k

Income taxes

€13k▼

2024 · €20k

Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.

Filed annual accounts

As filed with the NBB · 2025 against 2024

Balance sheet Code20242025

Assets

Total assets20/58€249k€107k▼

Fixed assets21/28€10k€4k▼

Tangible fixed assets22/27€10k€4k▼

Furniture and vehicles24€848-

Leasing and similar rights25€9k€4k▼

Current assets29/58€239k€103k▼

Amounts receivable within one year40/41€19k€35k▲

Trade receivables40€16k€26k▲

Other amounts receivable41€3k€9k▲

Cash at bank and in hand54/58€219k€66k▼

Deferred charges and accrued income490/1€2k€2k▲

Equity and liabilities

Total equity and liabilities10/49€249k€107k▼

Equity10/15€224k€85k▼

Contributions10/11€5k€5k=

Reserves13€219k€80k▼

Distributable reserves133€219k€80k▼

Amounts payable17/49€25k€22k▼

Amounts payable after more than one year17€4k-

Financial debts170/4€4k-

Amounts payable within one year42/48€21k€22k▲

Current portion of amounts payable after more than one year42€5k€4k▼

Trade debts44€2k€3k▲

Suppliers440/4€2k€3k▲

Taxes, remuneration and social security45€9k€15k▲

Taxes450/3€6k€10k▲

Remuneration and social security454/9€3k€5k▲

Other amounts payable47/48€5k€827▼

Accrued charges and deferred income492/3€275€275=

Income statement Code20242025

Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€6k€6k▼

Other operating charges640/8€1k€1k▲

Gross operating margin9900€104k€71k▼

Operating profit (loss)9901€97k€63k▼

Financial income75/76B€27€5▼

Recurring financial income75€27€5▼

Financial charges65/66B€239€242▲

Recurring financial charges65€239€242▲

Profit (loss) for the period before taxes9903€97k€63k▼

Income taxes67/77€20k€13k▼

Profit (loss) for the period9904€77k€50k▼

Profit (loss) for the period to be appropriated9905€77k€50k▼

Appropriation of the result

Profit (loss) to be appropriated9906€77k€50k▼

Transfer from equity791/2-€189k

Transfer to equity691/2€77k€50k▼

To other reserves6921€77k€50k▼

Profit to be distributed694/7-€189k

Return on contributions (dividend)694-€189k

The notes to these accounts (4 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

All 8Financial 4Filings 4

Next filing, fiscal year 2026, expected by 31-01-2027

2026

24-01

NBB filing Annual accounts filed

fiscal year 2025 · micro schema

2025

30-06

Financial Weakest financial yearnet €50k ▼35.1%

Net result drops to €50k, the lowest in the series.

24-01

NBB filing Annual accounts filed

fiscal year 2024 · micro schema

2024

30-06

Financial Equity above €200kEq €224k ▲52.2%

3 profitable years in a row build equity to €224k.

29-01

NBB filing Annual accounts filed

fiscal year 2023 · micro schema

2023

30-06

Financial Liquidity doublescurrent ratio 8.36

Current ratio from 3.99 to 8.36; short-term debt falls from €26k to €19k.

30-06

Financial Equity above €100kEq €147k ▲70.7%

2 profitable years in a row build equity to €147k.

31-01

NBB filing Annual accounts filed

fiscal year 2022 · micro schema

Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors

1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.

Location & real-estate footprint

Registered office, Gent · 1 establishment unit since 2021

establishment The establishment unit on the map

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

De Pintelaan 1649000 Gent

Ground area

103 m²

Building footprint

77 m²

Volume, LiDAR

501 m³

Parcel 44808H0189/00S002, Flanders · tallest building 10.9 m, ±2 floors. Linked by address, not a title deed.

1 establishment unit

PPPharmacy

De Pintelaan 164, 9000 GentRetail sale of pharmaceutical products

since 20212.316.517.574

1 parcel

Flanders 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
44808H0189/00S002	Flanders	103 m²	1 · 77 m²	10.9 m · 2 fl.

Linked by address, not proof of ownership

Methodology

via registered seat: 1

1 of 1 parcel with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Similar companies · same sector, comparable size

APOTHEEK PYLYSER SOFIE

MANAGEMENT LORMANS-BEKKERS

Sint-Jans-Molenbeek · Eq €85k

PHARMALIS

BE 0479.216.325

Neufchâteau · Eq €85k

Of 5,208 companies in sector 47730 we hold annual accounts for 3,850. 3,289 are within a factor 10 of this equity.See the whole sector

Company data · Crossroads Bank

Identification

Legal formPrivate limited company

Founded26-03-2021

Fiscal year end30-06

Activities, NACEBEL

47730Retail sale of pharmaceutical products

Sources

Crossroads Bank for EnterprisesNational Bank · 4 filingsAddress and cadastre registers

Data from official sources, last processed on 13-09-2026. Scores and ratios are computed by Checked and are not a credit decision.